ZNF483

Summary

ZNF483 (zinc finger protein 483, HGNC:23384) is a protein-coding gene on chromosome 9q31.3, encoding Zinc finger protein 483 (Q8TF39). May be involved in transcriptional regulation.

Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be active in nucleus.

Source: NCBI Gene 158399 — RefSeq curated summary.

At a glance

• Gene–disease (curated): primary ovarian failure (Moderate, GenCC)
• GWAS associations: 12
• Clinical variants (ClinVar): 68 total
• MANE Select transcript: NM_133464

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23384
Approved symbol	ZNF483
Name	zinc finger protein 483
Location	9q31.3
Locus type	gene with protein product
Status	Approved
Aliases	ZKSCAN16, KIAA1962, ZSCAN48
Ensembl gene	ENSG00000173258
Ensembl biotype	protein_coding
Entrez	158399

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 11 protein_coding

ENST00000309235, ENST00000355824, ENST00000358151, ENST00000374374, ENST00000904413, ENST00000904421, ENST00000904425, ENST00000920592, ENST00000920593, ENST00000920594, ENST00000920595

RefSeq mRNA: 2 — MANE Select: NM_133464 NM_001007169, NM_133464

CCDS: CCDS35105, CCDS35106

Canonical transcript exons

ENST00000309235 — 6 exons

Exon	Start	End
ENSE00001204835	111534261	111534353
ENSE00001204837	111533739	111533865
ENSE00001204838	111530875	111530963
ENSE00001204846	111541657	111555417
ENSE00001204849	111527268	111527807
ENSE00001946936	111525179	111525262

Expression profiles

Bgee: expression breadth ubiquitous, 239 present calls, max score 99.53.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 20.2253 / max 3631.4644, expressed in 1029 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
98007	20.0794	1029
98006	0.1459	85

Top tissues by expression

257 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	99.53	gold quality
middle temporal gyrus	UBERON:0002771	99.32	gold quality
Brodmann (1909) area 23	UBERON:0013554	99.29	gold quality
Brodmann (1909) area 46	UBERON:0006483	99.24	gold quality
postcentral gyrus	UBERON:0002581	99.16	gold quality
cerebellar vermis	UBERON:0004720	99.10	gold quality
entorhinal cortex	UBERON:0002728	99.06	gold quality
parietal lobe	UBERON:0001872	99.04	gold quality
pons	UBERON:0000988	98.91	gold quality
superior vestibular nucleus	UBERON:0007227	98.78	gold quality
substantia nigra pars compacta	UBERON:0001965	98.71	gold quality
lateral nuclear group of thalamus	UBERON:0002736	98.61	gold quality
substantia nigra pars reticulata	UBERON:0001966	98.54	gold quality
lateral globus pallidus	UBERON:0002476	98.06	gold quality
medulla oblongata	UBERON:0001896	98.05	gold quality
ventral tegmental area	UBERON:0002691	97.93	gold quality
corpus epididymis	UBERON:0004359	97.30	gold quality
dorsal plus ventral thalamus	UBERON:0001897	97.23	gold quality
germinal epithelium of ovary	UBERON:0001304	97.11	gold quality
caput epididymis	UBERON:0004358	96.88	gold quality
globus pallidus	UBERON:0001875	96.85	gold quality
cauda epididymis	UBERON:0004360	96.84	gold quality
subthalamic nucleus	UBERON:0001906	96.69	gold quality
superior frontal gyrus	UBERON:0002661	96.63	gold quality
medial globus pallidus	UBERON:0002477	96.58	gold quality
corpus callosum	UBERON:0002336	96.11	gold quality
adult organism	UBERON:0007023	96.08	gold quality
inferior vagus X ganglion	UBERON:0005363	95.96	gold quality
seminal vesicle	UBERON:0000998	94.37	gold quality
buccal mucosa cell	CL:0002336	94.18	gold quality

Single-cell (SCXA)

Detected in 9 experiment(s), a significant marker in 6.

Experiment	Marker?	Max mean expression
E-GEOD-83139	yes	2620.82
E-GEOD-109979	yes	2010.93
E-ENAD-27	yes	1964.43
E-MTAB-5061	yes	13.28
E-GEOD-84465	yes	6.54
E-GEOD-81547	yes	4.93
E-GEOD-70580	no	69.12
E-GEOD-81608	no	18.93
E-ANND-3	no	6.38

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

59 targeting ZNF483, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-548BB-3P	99.86	70.58	4354
HSA-MIR-548AC	99.84	70.77	4351
HSA-MIR-548H-3P	99.84	70.80	4349
HSA-MIR-548Z	99.84	70.80	4349
HSA-MIR-204-5P	99.79	71.62	2439
HSA-MIR-211-5P	99.79	71.65	2440
HSA-MIR-623	99.76	68.16	1170
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-518A-5P	99.70	69.01	2209
HSA-MIR-527	99.70	69.01	2209
HSA-MIR-4530	99.69	66.47	1509
HSA-MIR-4470	99.66	69.35	1767
HSA-MIR-4756-3P	99.62	66.30	1319
HSA-MIR-1915-3P	99.58	66.79	1988
HSA-MIR-3120-3P	99.54	70.28	2669
HSA-MIR-888-3P	99.53	69.77	1057
HSA-MIR-365A-3P	99.43	70.02	836
HSA-MIR-365B-3P	99.43	70.02	836
HSA-MIR-208A-5P	99.42	70.83	1913

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Zkscan16	ENSMUSG00000038630
rattus_norvegicus	Zkscan16	ENSRNOG00000084203

Paralogs (176): ZNF195 (ENSG00000005801), ZNF112 (ENSG00000062370), ZNF275 (ENSG00000063587), ZNF37A (ENSG00000075407), ZNF510 (ENSG00000081386), ZNF506 (ENSG00000081665), ZNF268 (ENSG00000090612), MZF1 (ENSG00000099326), ZNF629 (ENSG00000102870), ZNF175 (ENSG00000105497), ZNF85 (ENSG00000105750), ZFP30 (ENSG00000120784), ZNF45 (ENSG00000124459), ZNF391 (ENSG00000124613), ZNF436 (ENSG00000125945), ZNF484 (ENSG00000127081), ZNF835 (ENSG00000127903), ZNF780B (ENSG00000128000), ZSCAN10 (ENSG00000130182), ZNF317 (ENSG00000130803), ZNF331 (ENSG00000130844), ZNF227 (ENSG00000131115), ZNF141 (ENSG00000131127), ZNF132 (ENSG00000131849), ZNF189 (ENSG00000136870), ZIM3 (ENSG00000141946), ZFP14 (ENSG00000142065), ZNF514 (ENSG00000144026), ZNF300 (ENSG00000145908), RBAK (ENSG00000146587), ZNF157 (ENSG00000147117), ZNF182 (ENSG00000147118), ZNF41 (ENSG00000147124), ZNF7 (ENSG00000147789), ZNF117 (ENSG00000152926), ZNF221 (ENSG00000159905), ZNF235 (ENSG00000159917), ZNF714 (ENSG00000160352), ZNF577 (ENSG00000161551), ZNF12 (ENSG00000164631)

Protein

Protein identifiers

Zinc finger protein 483 — Q8TF39 (reviewed: Q8TF39)

Alternative names: Zinc finger protein with KRAB and SCAN domains 16

All UniProt accessions (3): Q8TF39, Q5VZN3, Q6P088

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8TF39-1	1	yes
Q8TF39-2	2

RefSeq proteins (2): NP_001007170, NP_597721* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR003309	SCAN_dom	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR038269	SCAN_sf	Homologous_superfamily
IPR050752	C2H2-ZF_domain	Family

Pfam: PF00096, PF01352, PF02023

UniProt features (28 total): zinc finger region 11, strand 4, region of interest 3, compositionally biased region 3, domain 2, splice variant 2, chain 1, sequence conflict 1, helix 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2CTU	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TF39-F1	64.91	0.04

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway

MSigDB gene sets: 78 (showing top): WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN, GOZGIT_ESR1_TARGETS_DN, CHANDRAN_METASTASIS_DN, BILD_E2F3_ONCOGENIC_SIGNATURE, RICKMAN_HEAD_AND_NECK_CANCER_A, SABATES_COLORECTAL_ADENOMA_DN, GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, LU_EZH2_TARGETS_DN, GRYDER_PAX3FOXO1_ENHANCERS_KO_DOWN, ZWANG_DOWN_BY_2ND_EGF_PULSE, E2F3_UP.V1_UP, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, TFEB_TARGET_GENES, MIR8485

GO Biological Process (2): regulation of transcription by RNA polymerase II (GO:0006357), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (6): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
transition metal ion binding	1
nucleic acid binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

626 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF483	ZNF462	Q96JM2	684
ZNF483	TMEM80	Q96HE8	529
ZNF483	PLEKHG7	Q6ZR37	431
ZNF483	WDR37	Q9Y2I8	412
ZNF483	GBP1	P32455	408
ZNF483	SMTNL2	Q2TAL5	403
ZNF483	KDM3B	Q7LBC6	403
ZNF483	RBM48	Q5RL73	398
ZNF483	MKRN3	Q13064	396
ZNF483	RMND5A	Q9H871	394
ZNF483	ZNHIT3	Q15649	385
ZNF483	JHY	Q6NUN7	378
ZNF483	TMEM213	A2RRL7	378
ZNF483	CLXN	Q9HAE3	362
ZNF483	KISS1R	Q969F8	360

IntAct

49 interactions, top by confidence:

A	B	Type	Score
MECP2	GTPBP10	psi-mi:“MI:0914”(association)	0.530
ZNF483	ZNF197	psi-mi:“MI:0914”(association)	0.530
ZNF18	ZMYM6	psi-mi:“MI:0914”(association)	0.530
TRIM28	ZNF316	psi-mi:“MI:0914”(association)	0.530
VTN	HAT1	psi-mi:“MI:0914”(association)	0.530
ABT1	ZNF316	psi-mi:“MI:0914”(association)	0.530
ZNF483	ZSCAN22	psi-mi:“MI:0915”(physical association)	0.400
CCDC59	IPO5	psi-mi:“MI:0914”(association)	0.350
DGCR8	MPHOSPH10	psi-mi:“MI:0914”(association)	0.350
VTN	HAT1	psi-mi:“MI:0914”(association)	0.350
C6orf11	RRP8	psi-mi:“MI:0914”(association)	0.350
CBX5	ZNF568	psi-mi:“MI:0914”(association)	0.350
SCRIB	C1orf226	psi-mi:“MI:0914”(association)	0.350
PURG	ZNF320	psi-mi:“MI:0914”(association)	0.350
ZNF467	ZNF320	psi-mi:“MI:0914”(association)	0.350
GOLGA8A	ZNF320	psi-mi:“MI:0914”(association)	0.350
NOTCH2	ZNF320	psi-mi:“MI:0914”(association)	0.350
LTBP2	ZNF320	psi-mi:“MI:0914”(association)	0.350
RPL36	GTPBP10	psi-mi:“MI:0914”(association)	0.350
RPL28	GTPBP10	psi-mi:“MI:0914”(association)	0.350
ABT1	GTPBP10	psi-mi:“MI:0914”(association)	0.350
ADARB1	GTPBP10	psi-mi:“MI:0914”(association)	0.350
MRPL10		psi-mi:“MI:0914”(association)	0.350
PNMA8A	AP3B1	psi-mi:“MI:0914”(association)	0.350
FGF13	MPHOSPH10	psi-mi:“MI:0914”(association)	0.350

BioGRID (82): ZNF483 (Two-hybrid), ZNF483 (Two-hybrid), ZNF483 (Two-hybrid), ZNF483 (Two-hybrid), ZNF483 (Two-hybrid), ZSCAN22 (Two-hybrid), ZYG11A (Affinity Capture-MS), TRIM24 (Affinity Capture-MS), ZKSCAN3 (Affinity Capture-MS), ZKSCAN4 (Affinity Capture-MS), ZNF174 (Affinity Capture-MS), ZNF197 (Affinity Capture-MS), ZNF483 (Affinity Capture-MS), SCAND1 (Affinity Capture-MS), ZKSCAN1 (Affinity Capture-MS)

ESM2 similar proteins: A0JPL0, A3KN36, A7MBI1, A8MT65, B2RXC5, D3ZVT0, P08042, P21506, P51508, P52738, Q02525, Q06730, Q12901, Q2KI58, Q2M218, Q2M3W8, Q2M3X9, Q2VY69, Q49AA0, Q4R6J4, Q4V8A8, Q5FWF6, Q5HY98, Q5RB33, Q5RC79, Q5REF1, Q5T5D7, Q5VIY5, Q61967, Q6P2D0, Q6ZN11, Q86XU0, Q86Y25, Q8N782, Q8N859, Q8NB42, Q8TF39, Q8TF47, Q8WXB4, Q95K49

Diamond homologs: A1YEP8, A1YEQ3, A1YEV9, A1YFW2, A1YFW6, A1YG26, A1YG48, A1YG60, A1YGJ4, A1YGK6, A2T6E3, A2T6V8, A2T6W2, A2T712, A2T736, A2T7D2, A2T7D7, A2T7F2, A2T7F4, A2T7L7, A2T812, A6QNZ0, A6QPT6, B2KFW1, O14709, O14771, O14978, O15535, O43309, O60304, O95125, P10073, P17022, P17028, P17029, P17040, P28698, P49910, P51815, P59923

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 49 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of miRNA transcription	5	33.8×	2e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

68 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	56
Likely benign	10
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1269 predictions. Top by Δscore:

Variant	Effect	Δscore
9:111530962:GT:G	donor_gain	1.0000
9:111530964:G:GG	donor_gain	1.0000
9:111534254:T:G	acceptor_gain	1.0000
9:111570086:CTTA:C	donor_loss	1.0000
9:111570087:TTAC:T	donor_loss	1.0000
9:111570088:TA:T	donor_loss	1.0000
9:111570089:A:AC	donor_gain	1.0000
9:111570090:C:CC	donor_gain	1.0000
9:111570090:CCT:C	donor_gain	1.0000
9:111570210:C:CC	acceptor_gain	1.0000
9:111574839:CTAC:C	acceptor_gain	1.0000
9:111525678:T:TA	acceptor_gain	0.9900
9:111527266:A:AG	acceptor_gain	0.9900
9:111527267:G:GA	acceptor_gain	0.9900
9:111533826:G:GT	donor_gain	0.9900
9:111533864:GG:G	donor_gain	0.9900
9:111533865:GG:G	donor_gain	0.9900
9:111534253:A:AG	acceptor_gain	0.9900
9:111534254:T:TA	acceptor_gain	0.9900
9:111570205:TGGGC:T	acceptor_gain	0.9900
9:111570206:GGGC:G	acceptor_gain	0.9900
9:111570207:GGC:G	acceptor_gain	0.9900
9:111570208:GC:G	acceptor_gain	0.9900
9:111570209:CC:C	acceptor_gain	0.9900
9:111570210:CT:C	acceptor_loss	0.9900
9:111570211:T:G	acceptor_loss	0.9900
9:111574728:CATTA:C	donor_loss	0.9900
9:111574730:TTA:T	donor_loss	0.9900
9:111574731:TA:T	donor_loss	0.9900
9:111574732:ACCTG:A	donor_loss	0.9900

AlphaMissense

4925 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:111542949:T:C	F672L	1.000
9:111542951:C:A	F672L	1.000
9:111542951:C:G	F672L	1.000
9:111542445:T:C	F504L	0.999
9:111542447:C:A	F504L	0.999
9:111542447:C:G	F504L	0.999
9:111542529:T:C	F532L	0.999
9:111542531:T:A	F532L	0.999
9:111542531:T:G	F532L	0.999
9:111542613:T:C	F560L	0.999
9:111542615:C:A	F560L	0.999
9:111542615:C:G	F560L	0.999
9:111542697:T:C	F588L	0.999
9:111542699:T:A	F588L	0.999
9:111542699:T:G	F588L	0.999
9:111542865:T:C	F644L	0.999
9:111542867:C:A	F644L	0.999
9:111542867:C:G	F644L	0.999
9:111542950:T:C	F672S	0.999
9:111542983:G:C	R683P	0.999
9:111543033:T:C	F700L	0.999
9:111543035:T:A	F700L	0.999
9:111543035:T:G	F700L	0.999
9:111542361:T:C	F476L	0.998
9:111542363:T:A	F476L	0.998
9:111542363:T:G	F476L	0.998
9:111542446:T:C	F504S	0.998
9:111542558:T:A	H541Q	0.998
9:111542558:T:G	H541Q	0.998
9:111542698:T:C	F588S	0.998

dbSNP variants (sampled 300 via entrez): RS1000032156 (9:111567663 T>C), RS1000052345 (9:111525681 T>C), RS1000083892 (9:111567971 G>T), RS1000088513 (9:111554439 C>G,T), RS1000300035 (9:111555015 G>A), RS1000331823 (9:111562164 C>T), RS1000455626 (9:111548701 T>C), RS1000495340 (9:111530311 G>A), RS1000741003 (9:111535900 C>A,T), RS1000760558 (9:111537244 CAG>C), RS1000824669 (9:111536117 C>T), RS1000850591 (9:111559826 A>G,T), RS1000875778 (9:111567380 G>A,C,T), RS1000913972 (9:111553177 A>C,G), RS1000917557 (9:111559745 C>T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
primary ovarian failure	Moderate	Autosomal dominant

Mondo (1): primary ovarian failure (MONDO:0005387)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

12 associations (top):

Study	Trait	p-value
GCST000880_11	Menarche (age at onset)	4.000000e-11
GCST001876_12	Pubertal anthropometrics	3.000000e-06
GCST001876_5	Pubertal anthropometrics	2.000000e-07
GCST001973_13	Menarche (age at onset)	2.000000e-06
GCST001973_5	Menarche (age at onset)	4.000000e-15
GCST002541_77	Menarche (age at onset)	1.000000e-08
GCST002541_78	Menarche (age at onset)	2.000000e-23
GCST003993_7	Menarche (age at onset)	2.000000e-08
GCST003994_3	Age at voice drop	1.000000e-07
GCST008839_468	Height	2.000000e-20
GCST008839_537	Height	4.000000e-07
GCST010241_227	Apolipoprotein A1 levels	2.000000e-09

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004703	age at menarche
EFO:0001382	puberty
EFO:0007888	age at voice drop
EFO:0004614	apolipoprotein A 1 measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression	3
sodium arsenite	decreases expression, increases expression	2
Vorinostat	affects cotreatment, decreases expression	2
Panobinostat	decreases expression, affects cotreatment	2
Benzo(a)pyrene	affects expression, increases methylation	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
kojic acid	decreases expression	1
arsenite	increases expression	1
potassium chromate(VI)	increases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
erucylphospho-N,N,N-trimethylpropylammonium	increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Acetaminophen	increases expression	1
Arbutin	decreases expression	1
Cisplatin	affects cotreatment, increases expression	1
Nickel	decreases expression	1
Vanadates	decreases expression	1
Asbestos, Serpentine	decreases expression	1
Asbestos, Crocidolite	decreases expression	1
Cadmium Chloride	increases expression	1

Clinical trials (associated diseases)

75 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists